Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
825 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02880371 | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 82 | PfizerINDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT03128411 | Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 64 | PfizerINDUSTRY | 1 | May 19, 2022 | clinicaltrials |
| NCT04115189 |
| A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA) |
| completed |
| — |
| 57 |
| PfizerINDUSTRY |
| 4 |
| May 10, 2022 |
| clinicaltrials |
| NCT00920816 | Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer | completed | Phase 3 | 492 | PfizerINDUSTRY | 14 | May 6, 2022 | clinicaltrials |
| NCT02315066 | Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 | completed | Phase 1 | 174 | PfizerINDUSTRY | 4 | Apr 21, 2022 | clinicaltrials |
| NCT03727750 | Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML | completed | Phase 4 | 51 | PfizerINDUSTRY | 6 | Mar 25, 2022 | clinicaltrials |
| NCT02493751 | A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100) | completed | Phase 1 | 55 | PfizerINDUSTRY | 3 | Feb 18, 2022 | clinicaltrials |
| NCT03538717 | "Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC" | completed | — | 157 | PfizerINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03637491 | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | terminated | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 3 | Jan 26, 2022 | clinicaltrials |
| NCT01945775 | A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)(EMBRACA) | completed | Phase 3 | 431 | PfizerINDUSTRY | 16 | Jan 20, 2022 | clinicaltrials |
| NCT02600923 | Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate | completed | Phase 3 | 131 | PfizerINDUSTRY | 4 | Jan 20, 2022 | clinicaltrials |
| NCT03916458 | REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA(ATILA) | completed | — | 62 | PfizerINDUSTRY | 1 | Dec 13, 2021 | clinicaltrials |
| NCT03499353 | Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | terminated | Phase 2 | 61 | PfizerINDUSTRY | 1 | Nov 9, 2021 | clinicaltrials |
| NCT01176916 | Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China | completed | Phase 4 | 564 | PfizerINDUSTRY | 1 | Oct 27, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT00880009 | Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer | terminated | Phase 2 | 16 | PfizerINDUSTRY | 7 | Sep 27, 2021 | clinicaltrials |
| NCT02092467 | Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis | completed | Phase 4 | 4,372 | PfizerINDUSTRY | 30 | Aug 17, 2021 | clinicaltrials |
| NCT03077607 | A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors | completed | Phase 1 | 36 | PfizerINDUSTRY | 4 | Jun 30, 2021 | clinicaltrials |
| NCT03031938 | Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies | completed | Phase 3 | 4 | PfizerINDUSTRY | 1 | Jun 25, 2021 | clinicaltrials |
| NCT01719380 | Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | completed | Phase 2 | 156 | PfizerINDUSTRY | 12 | Jun 23, 2021 | clinicaltrials |
| NCT00545129 | A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone | completed | Phase 2 | 59 | PfizerINDUSTRY | 13 | Jun 18, 2021 | clinicaltrials |
| NCT02349633 | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | terminated | Phase 1 / Phase 2 | 65 | PfizerINDUSTRY | 4 | Jun 10, 2021 | clinicaltrials |
| NCT04309617 | Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy | completed | — | 618 | PfizerINDUSTRY | 1 | May 19, 2021 | clinicaltrials |
| NCT02130557 | A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 3 | 536 | PfizerINDUSTRY | 26 | May 18, 2021 | clinicaltrials |
| NCT00830180 | Open Label Extension In Cancer Patients | completed | Phase 2 | 41 | PfizerINDUSTRY | 10 | Apr 5, 2021 | clinicaltrials |
| NCT01981187 | LGX818 for Patients With BRAFV600 Mutated Tumors(SIGNATURE) | terminated | Phase 2 | 12 | PfizerINDUSTRY | 1 | Mar 26, 2021 | clinicaltrials |
| NCT01763164 | Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma | completed | Phase 3 | 402 | PfizerINDUSTRY | 27 | Mar 22, 2021 | clinicaltrials |
| NCT02997176 | An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) | completed | Phase 1 | 38 | PfizerINDUSTRY | 1 | Feb 25, 2021 | clinicaltrials |
| NCT00585312 | Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)(CHIP) | terminated | Phase 3 | 106 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc.INDUSTRY | 14 | Feb 21, 2021 | clinicaltrials |
| NCT01885195 | MEK162 for Patients With RAS/RAF/MEK Activated Tumors(SIGNATURE) | completed | Phase 2 | 110 | PfizerINDUSTRY | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01945021 | Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC | completed | Phase 2 | 129 | PfizerINDUSTRY | 4 | Feb 21, 2021 | clinicaltrials |
| NCT00521638 | Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma | terminated | Phase 1 | 120 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Feb 18, 2021 | clinicaltrials |
| NCT01927341 | Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors | completed | Phase 1 / Phase 2 | 53 | PfizerINDUSTRY | 7 | Feb 18, 2021 | clinicaltrials |
| NCT00380874 | Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer | terminated | Phase 4 | 64 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc.INDUSTRY | 6 | Feb 11, 2021 | clinicaltrials |
| NCT00768664 | Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer | completed | Phase 2 | 69 | PfizerINDUSTRY | 1 | Feb 9, 2021 | clinicaltrials |
| NCT00637052 | A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia | completed | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 1 | Feb 8, 2021 | clinicaltrials |
| NCT00381095 | A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer(COPE) | terminated | Phase 4 | 152 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc.INDUSTRY | 19 | Jan 20, 2021 | clinicaltrials |
| NCT02997163 | An Open-Label Pharmacokinetics and Safety Study of Talazoparib | completed | Phase 1 | 34 | PfizerINDUSTRY | 2 | Jan 5, 2021 | clinicaltrials |
| NCT02222922 | A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 138 | PfizerINDUSTRY | 2 | Dec 17, 2020 | clinicaltrials |
| NCT02951156 | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)(Javelin DLBCL) | terminated | Phase 3 | 29 | PfizerINDUSTRY | 8 | Dec 17, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT01639001 | A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients | completed | Phase 3 | 207 | PfizerINDUSTRY | 5 | Dec 8, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials